Vascular Dementia
Conditions
Keywords
Dementia,vascular,rivastigmine,stroke,memory loss
Brief summary
The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
Interventions
DRUGRivastigmine
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Between the ages of 50 and 85 years old * Have contact with a responsible caregiver 3 or more days per week * Be male or a female who is surgically sterilized or one year post menopausal
Exclusion criteria
* Current diagnosis of severe or unstable cardiovascular or other diseases * Current diagnosis of active, uncontrolled seizure disorder, Parkinson's disease or Alzheimer's disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in cognition from baseline at week 24 | — |
| Global clinical impression of change from baseline at week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in activities of daily living from baseline at week 24 | — |
| Change in behavioral symptoms from baseline at week 24 | — |
| Change in clinical staging from baseline at week 24 | — |
Countries
Austria, Canada, France, Germany, Italy, Russia, Spain, Switzerland, United Kingdom, United States
Outcome results
None listed